Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in million yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The factors affecting performance were higher material and purchasing costs resulting from rising energy costs and transportation expenses in the medical gas-related business; firm performance by HOT and CPAP and rationalization measures in the home healthcare-related business; lower capital investment by medical institutions and the cancellation or postponement of projects due to surging construction costs in the medical gas equipment construction-related business; continued sales activities and the enhancement of the operating structure in the nursing and welfare-related business; and the provision of high-value-added services, personnel development, and improved occupancy and operating rates in the facility-based care-related business.
There are no applicable notes regarding the going concern assumption or significant events that raise substantial doubt about the going concern assumption.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | 15,520 million yen (YoY +2.8%) |
| Operating profit | 1,919 million yen (YoY -3.2%) |
| Ordinary income | 2,000 million yen (YoY -2.5%) |
| Profit attributable to owners of the parent | 1,372 million yen (YoY -6.2%) |
| Net income per share | ¥439.59 |
| Operating Margin | 12.4% |
| Equity ratio | End of the current fiscal period 74.8% / End of previous period 74.9% |
| Total assets | 26,743 million yen |
| Net assets | 20,325 million yen |
| Cash flows from operating activities | 2,477 million yen |
| Cash flows from investing activities | -1,543 million yen |
| Cash flows from financing activities | -948 million yen |
| Cash and cash equivalents at end of period | 5,910 million yen |
| Full-year earnings forecast | Net Sales 15,660 million yen (YoY +0.9%) / Operating profit 1,980 million yen (YoY +3.2%) / Ordinary income 2,060 million yen (YoY +3.0%) / Profit attributable to owners of the parent 1,400 million yen (YoY +2.0%) |
| Annual Dividend Forecast | 70 yen → 90 yen |
| Payout ratio | 20.5% actual for the fiscal year ended March 2026, 20.1% forecast for the fiscal year ending March 2027 |
| Segment revenue | Medical Gas Business 3,944.02 million yen (YoY -1.5%), Home Healthcare Business 7,226.32 million yen (YoY +7.4%), Medical Gas Equipment Construction Business 1,719.64 million yen (YoY -7.6%), Nursing Care and Welfare Business 1,194.42 million yen (YoY +2.8%), Residential Care Business 350.29 million yen (YoY +5.8%) |
| Segment profit | Medical Gas Business 461.74 million yen (YoY -27.4%), Home Healthcare Business 999.36 million yen (YoY +10.2%), Medical Gas Equipment Construction Business 276.00 million yen (YoY +1.4%), Nursing Care and Welfare Business 61.21 million yen (YoY +38.3%), Residential Care Business -15.57 million yen |
| Depreciation and amortization | 953 million yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets 694 thousand yen / Extraordinary loss Loss on Disposal of Fixed Assets 10,348 thousand yen |
| Disclosure regarding the going concern assumption | There are no applicable notes regarding the going concern assumption or significant events that raise substantial doubt about the going concern assumption. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New — companies (company name: none) / Excluded — companies (company name: none) |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable No / Subject person Not disclosed |
| Issued Shares at Period-End | 3,420,000 shares |
| Treasury Shares at Period-End | 295,100 shares |
| Factors Behind Changes in Business Performance | The factors affecting performance were higher material and purchasing costs resulting from rising energy costs and transportation expenses in the medical gas-related business; firm performance by HOT and CPAP and rationalization measures in the home healthcare-related business; lower capital investment by medical institutions and the cancellation or postponement of projects due to surging construction costs in the medical gas equipment construction-related business; continued sales activities and the enhancement of the operating structure in the nursing and welfare-related business; and the provision of high-value-added services, personnel development, and improved occupancy and operating rates in the facility-based care-related business. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the medical gas-related business, higher material and purchasing costs resulting from rising energy costs and transportation expenses reduced profit. In the home healthcare-related business, HOT and CPAP remained firm, and rationalization measures were advanced. In the medical gas equipment construction-related business, surging construction costs led to lower capital investment by medical institutions, as well as the cancellation or postponement of projects.